This clinical research study is a Phase 1 randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of MORAb-022 in healthy subjects and subjects with rheumatoid arthritis.
This study is currently recruiting healthy subjects to evaluate the safety and tolerability of single escalating intravenous (IV) doses of MORAb-022 in healthy subjects and subjects with rheumatoid arthritis (RA). This Phase 1 study is currently being conducted in Europe.
For more information about MORAb-022,
please click here (ClinicalTrials.gov Identifier: NCT01357759).
The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.